Kyung Sook Kim – CEO, Corestem, South Korea
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Address: 15F, Haesung-2-building, Teheran-Ro 508, Gangnam-gu ,Seoul, Republic of Korea 135-725
Tel: +82-2-2185-3800
Web: http://www.merck.co.kr/en/index.html;jsessionid=BD027DF767B36C40BA9C1C74E6E903E9
Merck Republic of Korea, a Republic of Korean subsidiary of Merck KGaA Germany, a global research-driven pharmaceutical company dedicated to putting patients first; Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. Merck Republic of Korea Ltd. was founded in 1989 and established Merck Advanced Technologies Ltd. (MAT) in 2002 to better serve the Republic of Korean display industry. In the same year, an R&D and production center for liquid crystals and a warehouse were opened in Poseung.Earlier in 2009, Merck announced it is investing 14 billion Republic of Korean Won (? 11 million) to establish an Advanced Technology Center in Republic of Korea to improve it’s R&D and manufacturing capacities.
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
